Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2003, for Phase III Medical, Inc. (formerly Corniche Group Incorporated). The Company discontinued its primary business of selling extended warranties and service contracts in June 2002 due to operating losses. It is currently in a transition phase, exploring opportunities to enter the medical and biotech sectors through acquisitions or technology partnerships. The Company has appointed Mark Weinreb as President and CEO to execute this new strategy. Management has raised substantial doubt about the Company's ability to continue as a going concern due to a lack of operations and insufficient means to finance current expenses.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2003 | Six Months Ended June 30, 2002 |
|---|---|---|
| Earned Revenues | $35,009 | $42,839 |
| Gross Profit | $9,909 | $9,775 |
| Operating Loss | $(328,159) | $(567,186) |
| Net Loss | $(390,566) | $(564,398) |
| Net Loss Attributable to Common Stockholders | $(414,408) | $(588,240) |
| Cash and Equivalents (End of Period) | $27,452 | $8,672 |
| Total Current Liabilities | $1,552,933 | $1,141,192 |
| Stockholders' Deficit | $(1,186,488) | $(823,895) |
Liquidity and Debt: The Company holds $27,452 in cash. Current liabilities exceed current assets by approximately $469,000. Significant liabilities include $409,354 in preferred dividends payable and $320,000 in notes payable. The Company relies on short-term loans and proceeds from promissory notes to meet cash needs.
Material Changes vs. Prior Period
- Revenue Decline: Earned revenues decreased by approximately 18% to $35,009 for the six months ended June 30, 2003, compared to $42,839 in the prior year. These revenues are residual from the discontinued warranty business.
- Reduced Operating Loss: The net loss decreased by 30.8% to $390,566 from $564,398 in the prior year. This improvement is primarily driven by a 41.4% reduction in selling, general, and administrative expenses ($338,068 vs. $576,961), resulting from lower payroll, legal fees, and the cessation of the warranty business operations.
- Interest Expense Surge: Interest expense increased significantly to $62,414 from $2,128 in the prior year due to new short-term loans secured in late 2002 and early 2003.
- Interest Income Collapse: Interest income dropped to $7 from $63,138 in the prior year, as the Company no longer earns interest on the defaulted StrandTek loans or marketable securities.
Outlook, Risks, and Contingencies
- Going Concern Uncertainty: The filing explicitly states that the Company has no operations or available means to finance current expenses, raising substantial doubt about its ability to continue as a going concern.
- Capital Needs: The Company must raise new capital to recruit personnel and execute its new medical/biotech business plan. There is no assurance that such capital can be raised or that the new business plan will succeed.
- Legal Proceedings (StrandTek): The Company obtained a final judgment of $1,415,622 against corporate defendants and $291,405 against each of four individual guarantors regarding a $1.25 million loan. However, the corporate defendants assigned assets for the benefit of creditors, making collection unlikely except against personal guarantors. Forbearance agreements were reached in July 2003 with three guarantors for installment payments.
- Debt Financing: The Company is actively selling promissory notes to accredited investors. As of the filing date, it had raised $171,000 net of costs in a $250,000 offering. Failure to raise the full amount may constrain startup activities.
- Preferred Stock Obligations: The Company has $681,174 in Series A Convertible Preferred Stock outstanding with cumulative dividends. Dividends payable have accrued to $409,354.
Investor Verification Checklist
- Cash Runway: Verify if the $27,452 cash balance is sufficient to cover immediate liabilities and operating costs given the lack of revenue.
- Debt Collection: Monitor the collection status of the StrandTek judgment against personal guarantors, as this is a primary source of potential liquidity.
- Capital Raise Progress: Confirm the status of the $250,000 promissory note offering and any subsequent equity financing efforts.
- Business Plan Execution: Assess whether the Company has secured any definitive agreements for the acquisition of medical/biotech assets or technologies.
- Preferred Stock Redemption: Review the terms regarding the redemption of Series A Preferred Stock and the impact of accrued dividends on common equity.